Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.
Indiana University Health Radiology, 714 N Senate Ave, Indianapolis, IN, 46202, USA.
Cardiovasc Intervent Radiol. 2024 Sep;47(9):1181-1189. doi: 10.1007/s00270-024-03819-5. Epub 2024 Aug 7.
Evaluate the outcomes of patients undergoing large-bore aspiration thrombectomy for the treatment of pulmonary embolism at a large university medical center.
All patients treated for pulmonary embolism with the FlowTriever System (Inari Medical, Irvine, CA) between September 2019 and January 2023 were retrospectively analyzed. The primary safety and effectiveness outcomes included 7- and 30-day all-cause mortality, major bleeding, procedure-associated clinical decompensation, pulmonary vascular or cardiac injury, and pulmonary artery pressure reduction. Additional outcomes included technical success (completing thrombectomy with the device as intended), changes in hemodynamics and supplemental oxygen requirements, and postprocedural intensive care unit stay.
A total of 286 patients were identified. The mean age was 60.5 years, and 90.9% of patients presented with intermediate-risk pulmonary embolism. Technical success was achieved in 96.9% (n = 277) of cases. The average reduction in mean pulmonary arterial pressure was 6.8 mmHg, from 28.7 ± 9.0 to 21.9 ± 8.0 mmHg (p < 0.0001). Two major bleeds (0.7%), 2 pulmonary vascular injuries (0.7%), and 4 (1.4%) procedure-associated decompensations were reported, but no device-related deaths occurred. The mean post-procedure intensive care unit stay was 2.0 ± 4.1 days, and 49.3% of patients had no postprocedural intensive care unit admittance. The overall 7-day and 30-day all-cause mortality rates were 2.4% and 6.7%, respectively, with a 30-day pulmonary embolism-related mortality rate of 3.5%.
This non-industry-sponsored single-center analysis of large-bore aspiration thrombectomy in a large population corroborates the findings of other studies and confirms that this approach is safe and effective for the treatment high- and intermediate-risk pulmonary embolism.
Retrospective observational study.
评估在一所大型大学医学中心接受大口径抽吸血栓切除术治疗肺栓塞的患者的结局。
回顾性分析了 2019 年 9 月至 2023 年 1 月期间使用 FlowTriever 系统(Inari Medical,加利福尼亚州欧文)治疗肺栓塞的所有患者。主要的安全性和有效性结局包括 7 天和 30 天全因死亡率、大出血、与操作相关的临床失代偿、肺血管或心脏损伤以及肺动脉压降低。其他结局包括技术成功率(按预期完成血栓切除术)、血液动力学和补充氧气需求的变化,以及术后重症监护病房停留时间。
共确定了 286 例患者。平均年龄为 60.5 岁,90.9%的患者存在中危肺栓塞。96.9%(n=277)的病例达到了技术成功。平均肺动脉压降低 6.8mmHg,从 28.7±9.0mmHg 降至 21.9±8.0mmHg(p<0.0001)。报告了 2 例大出血(0.7%)、2 例肺血管损伤(0.7%)和 4 例与操作相关的失代偿(1.4%),但无与器械相关的死亡。术后平均重症监护病房停留时间为 2.0±4.1 天,49.3%的患者无需入住术后重症监护病房。总的 7 天和 30 天全因死亡率分别为 2.4%和 6.7%,30 天肺栓塞相关死亡率为 3.5%。
这项非工业赞助的、针对大口径抽吸血栓切除术的大型人群的单中心分析结果与其他研究结果一致,证实了该方法治疗高危和中危肺栓塞的安全性和有效性。
证据水平 IV:回顾性观察研究。